Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Clinuvel Pharmaceuticals

- PMLiVE

Moving times

Continuity and stability are vital when it comes to the EMA's relocation when it leaves London

AstraZeneca AZ

AZ starts pursuit of lung cancer indication for Imfinzi

And its EGFR inhibitor Tagrisso picks up US breakthrough status

- PMLiVE

EMA sets aside £32m for temporary staff to help with Brexit move

As agency warns current tender system needs to be updated

EU flag

Europe’s cancer drug regulation is ‘broken’, claims study

Suggests EMA oncology approvals could lead to wasted funds and patient harm

- PMLiVE

EMA faces ‘permanent damage’ if forced to go to an unpopular city

Warns eight candidate cities wouldn't retain minimum staff numbers it needs

- PMLiVE

AZ buoyed by latest lung cancer data at ESMO

Data from separate Tagrisso and Imfinzi trials show superior PFS among patients

- PMLiVE

Takeda can’t sway NICE on oral myeloma therapy Ninlaro

Drug not recommended for NHS use in England and Wales

- PMLiVE

Dismay as NICE turns down first-line use of AZ’s Faslodex

Says evidence isn’t convincing for use in post-menopausal women

Roche Basel Switzerland

Roche claims its own CAR-T first with orphan drug Actemra

Comes as FDA approves the first CAR-T therapy from Novartis

UK Life Sciences Strategy - one year on

EMA starts firming up its stance on personalised medicines

But draft guidelines won't be ready much before 2019

- PMLiVE

Lynparza approval sets up tighter bout with PARP rivals

US regulator gives AZ the go-ahead for a new maintenance indication and formulation

AZ and Medimmune bolsters immuno-oncology leadership

Dr Jean-Charles Soria and Dr Geoffrey Kim join the company

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links